On Wednesday, Astera Labs earned a positive adjustment to its Relative Strength (RS) Rating, from 86 to 97.
IBD's proprietary rating measures share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks typically have an RS Rating of over 80 in the early stages of their moves.
Here Are 3 Keys For Successful Stock Investing
The IBD 50 stock is not currently showing a potential entry point. See if the stock goes on to build a chart pattern that could ignite a new run.
Astera Labs showed 0% earnings growth in the latest quarterly report. Revenue rose 206%.
Astera Labs holds the No. 5 rank among its peers in the Electronics-Semiconductor Fabless industry group. NVIDIA is the top-ranked stock within the group.
RELATED:
Chip Stocks To Watch And Semiconductor Industry News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
